For most of the 20th century, the brain was considered immune-privileged — a protected organ, sealed behind the blood-brain barrier, operating outside the reach of the peripheral immune system. Psychiatric conditions were understood through a neurochemical lens: serotonin deficits caused depression, dopamine dysregulation caused psychosis, and the treatments were drugs that targeted those neurotransmitters.
That model is incomplete. The field of psychoneuroimmunology (PNI) — the scientific study of the interactions between the immune system, the nervous system, and behavior — has fundamentally reframed our understanding of how mood disorders arise and persist. The evidence is now substantial: inflammation drives psychiatric symptoms, and for a significant proportion of people with treatment-resistant mental health conditions, immune dysregulation is the primary upstream cause.
What Is Psychoneuroimmunology?
Psychoneuroimmunology emerged as a formal discipline in the 1970s, pioneered by Robert Ader and Nicholas Cohen, who demonstrated that the immune system could be conditioned through psychological stimuli — a finding that proved the immune system and the nervous system were in active communication. Over subsequent decades, the bidirectional nature of this communication has been mapped in extraordinary detail.
The key insight of PNI is that the immune system, the nervous system, and the endocrine system do not operate independently. They share receptors, communicate via the same signaling molecules (cytokines, neurotransmitters, neuropeptides), and respond to each other's states in real time. Psychological stress alters immune function. Immune activation alters psychological states. The brain and the immune system are not separate systems with occasional crosstalk — they are integrated components of a single regulatory network.
The Cytokine Model of Depression
The cytokine model of depression, developed through the work of researchers including Andrew Miller, Charles Raison, and Michael Maes, proposes that elevated pro-inflammatory cytokines are a primary driver of depressive illness in a substantial subset of patients. The evidence supporting this model includes:
- Elevated levels of IL-6, IL-1β, TNF-α, and CRP are consistently found in meta-analyses of patients with major depressive disorder
- Administration of inflammatory cytokines (such as interferon-alpha for hepatitis C treatment) produces clinical depression in a significant percentage of recipients
- Anti-inflammatory interventions — including NSAIDs, omega-3 fatty acids, and targeted biologic therapies — demonstrate antidepressant effects in randomized controlled trials
- Patients with inflammatory conditions (rheumatoid arthritis, inflammatory bowel disease, psoriasis) have substantially elevated rates of depression and anxiety
- Treatment-resistant depression is disproportionately associated with elevated inflammatory markers
The clinical implication is direct: when standard antidepressant treatment fails, inflammatory status should be evaluated. A patient with elevated CRP and IL-6 who has not responded to SSRIs may be experiencing inflammation-driven depression that requires immune-targeted intervention, not higher doses of the same medication.
How Inflammation Disrupts Neurotransmitter Systems
Inflammation does not simply "cause" low mood as a vague downstream effect. It disrupts neurotransmitter synthesis and function through specific, well-characterized mechanisms.
The Tryptophan-Kynurenine Pathway
Tryptophan is the amino acid precursor to serotonin. Under normal conditions, approximately 95% of dietary tryptophan is available for conversion to serotonin, kynurenine, and other metabolites. Under inflammatory conditions, the enzyme indoleamine 2,3-dioxygenase (IDO) is activated by pro-inflammatory cytokines — particularly IFN-γ, TNF-α, and IL-6. IDO shunts tryptophan away from the serotonin pathway and toward the kynurenine pathway.
This produces two critical consequences:
- Serotonin depletion — less tryptophan is available for serotonin synthesis, directly reducing serotonergic tone in the brain
- Quinolinic acid accumulation — kynurenine is further metabolized to quinolinic acid, an NMDA receptor agonist and neurotoxin that damages hippocampal neurons, reduces neuroplasticity, and is found in elevated concentrations in the cerebrospinal fluid of suicidal patients
This is one reason why SSRIs — which act by increasing synaptic serotonin availability — are less effective in patients with high inflammatory burden. If IDO activation is consuming tryptophan faster than serotonin can be synthesized, increasing reuptake inhibition addresses the downstream signal while leaving the upstream disruption untouched.
BDNF Suppression and Neuroplasticity
Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival, growth, and differentiation of neurons. It is essential for hippocampal neurogenesis — the process by which new neurons are formed in the hippocampus throughout adult life — and for synaptic plasticity, the cellular basis of learning, memory, and mood regulation.
Pro-inflammatory cytokines suppress BDNF expression. Chronically low BDNF is one of the most consistent biological findings in major depression, and hippocampal volume reduction — directly linked to reduced BDNF — is documented in imaging studies of depressed patients. The effective antidepressants (including SSRIs, exercise, and ketamine) all increase BDNF. The inflammatory process works directly against this mechanism.
Dopamine and the Basal Ganglia
Inflammation also disrupts dopamine synthesis and release in the basal ganglia — the brain region governing motivation, reward processing, and psychomotor activity. Elevated TNF-α reduces dopamine release in the striatum and alters dopamine transporter function, producing the anhedonia (loss of pleasure and motivation), psychomotor slowing, and fatigue that characterize the inflammatory subtype of depression. These symptoms are often the most treatment-resistant and the most functionally disabling.
Glutamate Excitotoxicity
Inflammation dysregulates glutamate — the brain's primary excitatory neurotransmitter — through multiple mechanisms, including reduced astrocyte glutamate reuptake and quinolinic acid-driven NMDA receptor activation. The result is glutamate excitotoxicity: excessive neuronal stimulation that damages and kills neurons, particularly in the hippocampus and prefrontal cortex. This mechanism is implicated in depression, PTSD, and the cognitive decline associated with chronic inflammatory conditions.
Neuroinflammation: When the Brain Itself Is Inflamed
Neuroinflammation refers specifically to inflammation within the central nervous system, driven primarily by microglial activation. Microglia are the brain's resident immune cells — approximately 10–15% of all brain cells — responsible for immune surveillance, synaptic pruning, debris clearance, and the brain's response to injury and infection.
Under normal conditions, microglia exist in a surveilling state. When activated by peripheral inflammation signals, direct infection, injury, or toxic exposure, they shift to a reactive state — releasing pro-inflammatory cytokines, reactive oxygen species, and glutamate. In the short term, this is protective. When activation becomes chronic, it is destructive.
Chronic microglial activation produces:
- Sustained neuroinflammation that disrupts synaptic function and neurotransmitter balance
- Dysregulated synaptic pruning, associated with schizophrenia, OCD, and autism spectrum conditions
- Impaired neurogenesis and reduced BDNF
- Progressive neuronal damage in vulnerable brain regions
PET imaging studies using TSPO tracers (a marker of microglial activation) have documented elevated neuroinflammation in patients with depression, PTSD, OCD, bipolar disorder, and schizophrenia — confirming that neuroinflammation is not a theoretical construct but a measurable biological reality in psychiatric populations.
Sources of Neuroinflammation: The Upstream Drivers
Identifying that neuroinflammation is driving psychiatric symptoms is clinically useful only if the source of that inflammation can be identified and addressed. The most common upstream drivers include:
Gut Dysbiosis and Intestinal Permeability
A disrupted gut microbiome and increased intestinal permeability (leaky gut) allow bacterial lipopolysaccharides (LPS) and other microbial products to enter systemic circulation, triggering persistent immune activation. This gut-derived inflammatory signal reaches the brain via the circulation, the vagus nerve, and immune cell trafficking. Gut-driven neuroinflammation is now a major research focus in depression and anxiety.
Chronic Infections
Reactivated Epstein-Barr virus, chronic Lyme disease (Borrelia), Mycoplasma, Herpes Simplex Virus, Cytomegalovirus, and Toxoplasma gondii all drive persistent immune activation and neuroinflammation. The psychiatric sequelae of these infections are increasingly recognized: depression, anxiety, cognitive impairment, and psychotic symptoms can all be infection-mediated.
Mold and Mycotoxin Exposure
Mycotoxins produced by mold in water-damaged buildings are potent inflammogens. They activate the NLRP3 inflammasome, suppress regulatory T-cell function, and produce a clinical syndrome that closely mimics treatment-resistant depression and anxiety with cognitive dysfunction. Mold illness (CIRS — chronic inflammatory response syndrome) is underdiagnosed but increasingly recognized as a psychiatric trigger.
Heavy Metals and Environmental Toxins
Mercury, lead, arsenic, and cadmium are neurotoxic and pro-inflammatory. Mercury in particular accumulates in brain tissue, disrupts microglial function, impairs mitochondrial electron transport, and promotes reactive oxygen species production. Organophosphate pesticides and endocrine-disrupting chemicals similarly drive neuroinflammation through oxidative stress and immune dysregulation.
Psychological Trauma and Chronic Stress
Chronic psychological stress activates the HPA axis and the sympathetic nervous system, both of which have direct pro-inflammatory effects. Cortisol, normally anti-inflammatory in acute settings, becomes pro-inflammatory under chronic secretion as glucocorticoid receptor resistance develops. Early adverse childhood experiences (ACEs) produce lasting epigenetic changes in inflammatory gene expression, explaining why trauma survivors carry an elevated inflammatory burden decades after the traumatic events.
Dietary Patterns
Ultra-processed food, refined sugar, industrial seed oils high in omega-6 fatty acids, and food sensitivities (particularly to gluten and dairy in susceptible individuals) all drive systemic inflammation. The "dietary inflammatory index" predicts depression risk in population studies. Conversely, Mediterranean-pattern diets rich in omega-3 fatty acids, polyphenols, and fermented foods are associated with reduced depression incidence and severity.
Measuring Neuroinflammation Clinically
While PET imaging is the gold standard for direct neuroinflammation assessment, it is not clinically accessible for most patients. Practical surrogate markers include:
- High-sensitivity CRP (hsCRP) — a sensitive marker of systemic inflammation; levels above 1 mg/L are associated with elevated depression risk
- IL-6 — one of the most consistently elevated cytokines in depression; available through specialty labs
- TNF-α — elevated in treatment-resistant depression and associated with anhedonia and psychomotor slowing
- Ferritin — an acute-phase reactant that rises with inflammation; very high or very low ferritin both warrant investigation
- Homocysteine — elevated levels indicate methylation impairment and are independently associated with depression and cognitive decline
- Kynurenine/tryptophan ratio — a direct measure of IDO activation and tryptophan shunting; elevated ratio indicates active inflammatory depletion of serotonin precursors
- Omega-3 index — low EPA+DHA as a percentage of red blood cell fatty acids predicts depression risk and anti-inflammatory intervention response
Anti-Inflammatory Interventions for Mental Health
If inflammation is a primary driver, then anti-inflammatory interventions should have psychiatric effects — and the evidence confirms they do.
- Omega-3 fatty acids (EPA-dominant) — Multiple RCTs demonstrate antidepressant effects of high-dose EPA supplementation. A 2019 meta-analysis in Translational Psychiatry confirmed EPA (not DHA) as the active antidepressant fraction, with effects comparable to antidepressant medication in inflammatory-subtype depression
- Curcumin — Inhibits NF-κB, suppresses IDO activation, and increases BDNF. RCT evidence supports antidepressant effects, particularly in combination with piperine for bioavailability
- Low-dose naltrexone (LDN) — Modulates microglial activation and reduces pro-inflammatory cytokine production; emerging evidence in treatment-resistant depression, fibromyalgia, and inflammatory conditions with psychiatric comorbidity
- Dietary intervention — The SMILES trial (2017) demonstrated that a Mediterranean diet intervention produced greater depression remission than social support alone, with a number-needed-to-treat of 4.1
- Exercise — Reduces IL-6, TNF-α, and CRP; increases BDNF and IL-10 (anti-inflammatory); one of the most robustly evidenced anti-inflammatory and antidepressant interventions available
- Gut restoration — Probiotic supplementation reduces inflammatory markers and depressive symptoms in clinical trials, particularly strains including Lactobacillus rhamnosus, Bifidobacterium longum, and Lactobacillus helveticus
- Targeted infection treatment — When chronic infection is identified as an inflammatory driver, appropriate antimicrobial or antiviral treatment can produce dramatic psychiatric improvement in patients who have not responded to standard care
The Clinical Takeaway
Psychoneuroimmunology is not a fringe theory. It is a mature scientific discipline supported by decades of peer-reviewed research, documented in the highest-impact journals in psychiatry, immunology, and neuroscience. Its clinical implications are direct and actionable:
- Inflammatory markers should be assessed in patients with mood disorders, particularly those who are treatment-resistant
- Upstream sources of inflammation should be identified and addressed systematically
- Anti-inflammatory interventions — dietary, nutritional, and where indicated pharmacological — should be incorporated into mental health treatment plans
- The question is not whether inflammation affects mental health. It is which inflammatory drivers are active in this specific patient, and how to address them
This is the science that underlies every protocol, every nutritional recommendation, and every intervention in this hub. Inflammation is the thread that connects the gut to the brain, the immune system to the mind, and the biological to the psychological. Follow the thread, and the path to recovery becomes visible.
Continue Reading
This article is part of the Mental Health & Your Mood hub. Continue with: